Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies

  title={Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: A review of controlled and naturalistic studies},
  author={Mats Fredriksen and Anne Halm{\o}y and Stephen V. Faraone and Jan Haavik},
  journal={European Neuropsychopharmacology},

Tables from this paper

Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials

Overall, ATX had a clinically significant effect in adults with ADHD, with reductions in core symptoms and clinically meaningful responder rates.

Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity

Overall, MPH is an effective ADHD treatment with a good safety profile and data suggest that dose optimization may enhance the safety and efficacy of treatment; further research is required to establish the extent to which short-term clinical benefits of MPH dose optimization translate into improved long-term outcomes for patients with ADHD.

Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.

Treatment with stimulants and atomoxetine of adults with ADHD has long-term beneficial effects and is tolerated but more longitudinal studies should be performed.

The Evidence of the Benefits and Harms of Methylphenidate in the Treatment of Attention Deficit / Hyperactivity Disorder is Inconclusive

The findings of trials assessing efficacy and safety of methylphenidate over short time periods need to be interpreted with caution and cannot be extrapolated to long-term effects, and the therapeutic value of this compound may be outweighed by its adverse effects.

Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine

A systematic review and meta-analysis of the effects of methylphenidate, amphetamines, and atomoxetine on diastolic and systolic blood pressure (DBP, SBP) and heart rate (HR) in children and adolescents with ADHD found no significant differences between the three medications.

Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.

Very low-certainty evidence is found that, compared with placebo, IR methylphenidate may reduce the clinical impression of the severity of ADHD symptoms and the effect of IR methyl Phenidate on ADHD symptoms was moderate, but the certainty of the evidence is very low.

[Pharmacotherapy of attention deficit hyperactivity disorder in adults].

The evidence for pharmacotherapy of ADHD and its implementation into treatment of adult patients is presented and an improvement in everyday functionality and quality of life under medication could also be shown in several studies.

Treatment of Adult ADHD without Stimulants: Effectiveness in A Dually Diagnosed Correctional Population

It does appear that nonstimulants are effective in this population of patients with substance use disorders, residing in a correctional community center for treatment and reintegration purposes, and it is speculated that the response and remission rate could be improved by adding ADHD specific psychosocial interventions.

Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review

While available evidence addressed mainly the efficacy and tolerability of psychostimulants and non-psychostimULants for ADHD core symptoms in the short term, further empirical support is needed for the non-pharmacological and multimodal treatments.



Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD

In conclusion, the short-term benefits of OROS-MPH continue during long-term open-label treatment, and maintenance of efficacy in a placebo-controlled withdrawal design remains to be confirmed in larger patient populations.

Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis.

The results of this interim analysis of an ongoing, open-label study of adults with ADHD support the long-term efficacy, safety, and tolerability of atomoxetine for the treatment of adult ADHD.

Long-Term Safety and Effectiveness of Mixed Amphetamine Salts Extended Release in Adults With ADHD

Treatment with MAS XR 20–60 mgl day for adult ADHD was generally well tolerated and was associated with sustained symptomatic improvement for up to 24 months.

Long-Term Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder: An Open-Label, Dose-Titration, 1-Year Study

OROS methylphenidate, in the flexible dosage range from 36 to 108 mg/d, was well tolerated for up to 1 year in adults with ADHD.

Long-Term, Open-Label Safety and Efficacy of Atomoxetine in Adults With ADHD

Results of this open-label study support the long-term efficacy, safety, and tolerability of atomoxetine for the treatment of adult ADHD.

Using long-acting stimulants: does it change ADHD treatment outcome?

  • J. SwansonL. Hechtman
  • Medicine
    The Canadian child and adolescent psychiatry review = La revue canadienne de psychiatrie de l'enfant et de l'adolescent
  • 2005
Concerta(R) OROS-MPH releases methylphenidate (MPH) in an initial bolus, followed by increasing concentrations throughout the day, which overcomes the development of acute tolerance and produces significantly higher remission rates than immediate-release MPH.

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study.

The long-term treatment outcome shows that stimulants are effective in adult ADHD and side effects tend to be mild.

Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.

OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study.

This open-label trial followed a previously reported randomized, placebo-controlled trial of osmotic release oral system (OROS) methylphenidate (MPH) for the treatment of personality disorder (PD) and all ADHD subgroups showed similar, well-maintained improvement.